- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03322189
Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)
January 22, 2019 updated by: Data Collection Analysis Business Management
Medical Provider Experience and Assessment on Documenting Prescribing and Plan of Care Changes Due to Pharmacogenomics Testing
Current providers' standard operating procedures on pharmacogenomic testing patients
Study Overview
Detailed Description
The general design of this study is collecting data and reviewing Principal Investigators' Standard Operating Procedures on Pharmacogenomic testing and changes made to their specific SOP.
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Land O' Lakes, Florida, United States, 33558
- DCABM
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Current standard operating procedures for providers
Description
Inclusion Criteria:
Must be a Medical Practitioner
- Medical Doctor (MD)
- Doctor of Osteopathic (DO)
- Physician Assistant (PA)
- Advanced Practice Registered Nurse (APRN)
- Nurse Practioner (NP)
- Must have a current standard operating procedure that includes obtaining/reviewing medical history.
Exclusion Criteria:
- Government-funded insurance data cannot be included in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Provider Structures and Processes
Time Frame: 36 months
|
Plan of Care Changes due to Pharmacogenomic testing.
Provider based observational survey system on the health and well-being of patients and populations
|
36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 22, 2017
Primary Completion (Anticipated)
March 22, 2020
Study Completion (Anticipated)
April 1, 2020
Study Registration Dates
First Submitted
October 24, 2017
First Submitted That Met QC Criteria
October 25, 2017
First Posted (Actual)
October 26, 2017
Study Record Updates
Last Update Posted (Actual)
January 23, 2019
Last Update Submitted That Met QC Criteria
January 22, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- PAS1463
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacogenomic
-
Ain Shams UniversityCompletedPharmacokinetics | PharmacogenomicEgypt
-
Geisinger ClinicActive, not recruitingPolypharmacy | Pharmacogenomic TestingUnited States
-
Yale UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingContraception | Pharmacogenomic Drug InteractionUnited States
-
University of PittsburghUniversity of Pittsburgh Medical CenterEnrolling by invitationPharmacogenetics | Pharmacogenomic Drug InteractionUnited States
-
ClinLogic LLCRecruitingPharmacogenomic Testing for Medication ManagementUnited States
-
University of PittsburghPennsylvania Department of HealthNot yet recruitingPharmacogenetics | Community Pharmacy Services | Depression - Major Depressive Disorder | Pharmacogenomic Drug InteractionUnited States
-
Vanderbilt University Medical CenterActive, not recruitingPharmacogenomic TestingUnited States
-
Florida Atlantic UniversityRecruitingFall | Pharmacogenomic Testing | Adverse Drug Events | Poly Pharmacy | Fall Accident | Pharmacogenomic Drug InteractionUnited States
-
University of FloridaNational Human Genome Research Institute (NHGRI)RecruitingPharmacogenomic Drug InteractionUnited States
-
Second Affiliated Hospital, School of Medicine,...CompletedDepressive Disorder | Pharmacogenomic Drug InteractionChina
Clinical Trials on pharmacogenomic
-
M.D. Anderson Cancer CenterCompletedMetastatic Carcinoma in the Adrenal Cortex | Stage III Adrenal Cortex Carcinoma AJCC v8 | Stage IV Adrenal Cortex Carcinoma AJCC v8 | Unresectable Adrenal Cortex CarcinomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Peloton Therapeutics, Inc.CompletedRecurrent GlioblastomaUnited States
-
Wake Forest University Health SciencesTerminatedMalignant Tumor of Ill-defined SiteUnited States
-
Tabula Rasa HealthCareWithdrawnElderly | Adverse Drug Event | Pharmacogenomics | Drug Drug InteractionUnited States
-
Tabula Rasa HealthCareEnrolling by invitationPolypharmacy | PharmacogenomicsUnited States
-
Mayo ClinicCompleted
-
Auburn UniversityTuscaloosa Veterans Affairs Medical CenterWithdrawnDepressive Disorder, Major | Pharmacogenetics | Medication Therapy ManagementUnited States
-
Wake Forest University Health SciencesCompleted
-
Wake Forest University Health SciencesCompletedOncology | Hematopoietic Cell TransplantationUnited States
-
University Hospital, MontpellierCompletedCentral Nervous System LymphomaFrance